Literature DB >> 25381129

Characterization of gene mutations and copy number changes in acute myeloid leukemia using a rapid target enrichment protocol.

Niccolò Bolli1, Nicla Manes2, Thomas McKerrell3, Jianxiang Chi4, Naomi Park5, Gunes Gundem6, Michael A Quail5, Vijitha Sathiaseelan6, Bram Herman7, Charles Crawley8, Jenny I O Craig8, Natalie Conte9, Carolyn Grove3, Elli Papaemmanuil6, Peter J Campbell6, Ignacio Varela10, Paul Costeas11, George S Vassiliou12.   

Abstract

Prognostic stratification is critical for making therapeutic decisions and maximizing survival of patients with acute myeloid leukemia. Advances in the genomics of acute myeloid leukemia have identified several recurrent gene mutations whose prognostic impact is being deciphered. We used HaloPlex target enrichment and Illumina-based next generation sequencing to study 24 recurrently mutated genes in 42 samples of acute myeloid leukemia with a normal karyotype. Read depth varied between and within genes for the same sample, but was predictable and highly consistent across samples. Consequently, we were able to detect copy number changes, such as an interstitial deletion of BCOR, three MLL partial tandem duplications, and a novel KRAS amplification. With regards to coding mutations, we identified likely oncogenic variants in 41 of 42 samples. NPM1 mutations were the most frequent, followed by FLT3, DNMT3A and TET2. NPM1 and FLT3 indels were reported with good efficiency. We also showed that DNMT3A mutations can persist post-chemotherapy and in 2 cases studied at diagnosis and relapse, we were able to delineate the dynamics of tumor evolution and give insights into order of acquisition of variants. HaloPlex is a quick and reliable target enrichment method that can aid diagnosis and prognostic stratification of acute myeloid leukemia patients. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25381129      PMCID: PMC4803131          DOI: 10.3324/haematol.2014.113381

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  33 in total

1.  Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring.

Authors:  Rajyalakshmi Luthra; Keyur P Patel; Neelima G Reddy; Varan Haghshenas; Mark J Routbort; Michael A Harmon; Bedia A Barkoh; Rashmi Kanagal-Shamanna; Farhad Ravandi; Jorge E Cortes; Hagop M Kantarjian; L Jeffrey Medeiros; Rajesh R Singh
Journal:  Haematologica       Date:  2013-10-18       Impact factor: 9.941

2.  Functional heterogeneity of genetically defined subclones in acute myeloid leukemia.

Authors:  Jeffery M Klco; David H Spencer; Christopher A Miller; Malachi Griffith; Tamara L Lamprecht; Michelle O'Laughlin; Catrina Fronick; Vincent Magrini; Ryan T Demeter; Robert S Fulton; William C Eades; Daniel C Link; Timothy A Graubert; Matthew J Walter; Elaine R Mardis; John F Dipersio; Richard K Wilson; Timothy J Ley
Journal:  Cancer Cell       Date:  2014-03-06       Impact factor: 31.743

3.  Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing.

Authors:  Li Ding; Timothy J Ley; David E Larson; Christopher A Miller; Daniel C Koboldt; John S Welch; Julie K Ritchey; Margaret A Young; Tamara Lamprecht; Michael D McLellan; Joshua F McMichael; John W Wallis; Charles Lu; Dong Shen; Christopher C Harris; David J Dooling; Robert S Fulton; Lucinda L Fulton; Ken Chen; Heather Schmidt; Joelle Kalicki-Veizer; Vincent J Magrini; Lisa Cook; Sean D McGrath; Tammi L Vickery; Michael C Wendl; Sharon Heath; Mark A Watson; Daniel C Link; Michael H Tomasson; William D Shannon; Jacqueline E Payton; Shashikant Kulkarni; Peter Westervelt; Matthew J Walter; Timothy A Graubert; Elaine R Mardis; Richard K Wilson; John F DiPersio
Journal:  Nature       Date:  2012-01-11       Impact factor: 49.962

4.  Accurate detection of subclonal single nucleotide variants in whole genome amplified and pooled cancer samples using HaloPlex target enrichment.

Authors:  Eva C Berglund; Carl Mårten Lindqvist; Shahina Hayat; Elin Övernäs; Niklas Henriksson; Jessica Nordlund; Per Wahlberg; Erik Forestier; Gudmar Lönnerholm; Ann-Christine Syvänen
Journal:  BMC Genomics       Date:  2013-12-05       Impact factor: 3.969

5.  Discovery and saturation analysis of cancer genes across 21 tumour types.

Authors:  Michael S Lawrence; Petar Stojanov; Craig H Mermel; James T Robinson; Levi A Garraway; Todd R Golub; Matthew Meyerson; Stacey B Gabriel; Eric S Lander; Gad Getz
Journal:  Nature       Date:  2014-01-05       Impact factor: 49.962

6.  Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Luca Malcovati; Sudhir Tauro; Gunes Gundem; Peter Van Loo; Chris J Yoon; Peter Ellis; David C Wedge; Andrea Pellagatti; Adam Shlien; Michael John Groves; Simon A Forbes; Keiran Raine; Jon Hinton; Laura J Mudie; Stuart McLaren; Claire Hardy; Calli Latimer; Matteo G Della Porta; Sarah O'Meara; Ilaria Ambaglio; Anna Galli; Adam P Butler; Gunilla Walldin; Jon W Teague; Lynn Quek; Alex Sternberg; Carlo Gambacorti-Passerini; Nicholas C P Cross; Anthony R Green; Jacqueline Boultwood; Paresh Vyas; Eva Hellstrom-Lindberg; David Bowen; Mario Cazzola; Michael R Stratton; Peter J Campbell
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113

7.  Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis.

Authors:  Lambert Busque; Jay P Patel; Maria E Figueroa; Aparna Vasanthakumar; Sylvie Provost; Zineb Hamilou; Luigina Mollica; Juan Li; Agnes Viale; Adriana Heguy; Maryam Hassimi; Nicholas Socci; Parva K Bhatt; Mithat Gonen; Christopher E Mason; Ari Melnick; Lucy A Godley; Cameron W Brennan; Omar Abdel-Wahab; Ross L Levine
Journal:  Nat Genet       Date:  2012-09-23       Impact factor: 38.330

8.  Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.

Authors:  T Haferlach; Y Nagata; V Grossmann; Y Okuno; U Bacher; G Nagae; S Schnittger; M Sanada; A Kon; T Alpermann; K Yoshida; A Roller; N Nadarajah; Y Shiraishi; Y Shiozawa; K Chiba; H Tanaka; H P Koeffler; H-U Klein; M Dugas; H Aburatani; A Kohlmann; S Miyano; C Haferlach; W Kern; S Ogawa
Journal:  Leukemia       Date:  2013-11-13       Impact factor: 11.528

9.  Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.

Authors:  Niccolo Bolli; Hervé Avet-Loiseau; David C Wedge; Peter Van Loo; Ludmil B Alexandrov; Inigo Martincorena; Kevin J Dawson; Francesco Iorio; Serena Nik-Zainal; Graham R Bignell; Jonathan W Hinton; Yilong Li; Jose M C Tubio; Stuart McLaren; Sarah O' Meara; Adam P Butler; Jon W Teague; Laura Mudie; Elizabeth Anderson; Naim Rashid; Yu-Tzu Tai; Masood A Shammas; Adam S Sperling; Mariateresa Fulciniti; Paul G Richardson; Giovanni Parmigiani; Florence Magrangeas; Stephane Minvielle; Philippe Moreau; Michel Attal; Thierry Facon; P Andrew Futreal; Kenneth C Anderson; Peter J Campbell; Nikhil C Munshi
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919

10.  Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia.

Authors:  Liran I Shlush; Sasan Zandi; Amanda Mitchell; Weihsu Claire Chen; Joseph M Brandwein; Vikas Gupta; James A Kennedy; Aaron D Schimmer; Andre C Schuh; Karen W Yee; Jessica L McLeod; Monica Doedens; Jessie J F Medeiros; Rene Marke; Hyeoung Joon Kim; Kwon Lee; John D McPherson; Thomas J Hudson; Andrew M K Brown; Fouad Yousif; Quang M Trinh; Lincoln D Stein; Mark D Minden; Jean C Y Wang; John E Dick
Journal:  Nature       Date:  2014-02-12       Impact factor: 69.504

View more
  19 in total

1.  Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.

Authors:  N Bolli; G Biancon; M Moarii; S Gimondi; Y Li; C de Philippis; F Maura; V Sathiaseelan; Y-T Tai; L Mudie; S O'Meara; K Raine; J W Teague; A P Butler; C Carniti; M Gerstung; T Bagratuni; E Kastritis; M Dimopoulos; P Corradini; K Anderson; P Moreau; S Minvielle; P J Campbell; E Papaemmanuil; H Avet-Loiseau; N C Munshi
Journal:  Leukemia       Date:  2017-12-06       Impact factor: 11.528

Review 2.  Diagnosis and classification of hematologic malignancies on the basis of genetics.

Authors:  Justin Taylor; Wenbin Xiao; Omar Abdel-Wahab
Journal:  Blood       Date:  2017-06-09       Impact factor: 22.113

3.  Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy.

Authors:  Yan-Ping Xu; Lei Lv; Ying Liu; Matthew D Smith; Wen-Cai Li; Xian-Ming Tan; Meng Cheng; Zhijun Li; Michael Bovino; Jeffrey Aubé; Yue Xiong
Journal:  J Clin Invest       Date:  2019-07-16       Impact factor: 14.808

4.  Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia.

Authors:  Carmen Vicente; Claire Schwab; Michaël Broux; Ellen Geerdens; Sandrine Degryse; Sofie Demeyer; Idoya Lahortiga; Alannah Elliott; Lucy Chilton; Roberta La Starza; Cristina Mecucci; Peter Vandenberghe; Nicholas Goulden; Ajay Vora; Anthony V Moorman; Jean Soulier; Christine J Harrison; Emmanuelle Clappier; Jan Cools
Journal:  Haematologica       Date:  2015-07-23       Impact factor: 9.941

Review 5.  BCOR gene alterations in hematologic diseases.

Authors:  Paolo Sportoletti; Daniele Sorcini; Brunangelo Falini
Journal:  Blood       Date:  2021-12-16       Impact factor: 22.113

6.  A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma.

Authors:  N Bolli; Y Li; V Sathiaseelan; K Raine; D Jones; P Ganly; F Cocito; G Bignell; M A Chapman; A S Sperling; K C Anderson; H Avet-Loiseau; S Minvielle; P J Campbell; N C Munshi
Journal:  Blood Cancer J       Date:  2016-09-02       Impact factor: 11.037

7.  Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemia.

Authors:  P Richter-Pechańska; J B Kunz; J Hof; M Zimmermann; T Rausch; O R Bandapalli; E Orlova; G Scapinello; J C Sagi; M Stanulla; M Schrappe; G Cario; R Kirschner-Schwabe; C Eckert; V Benes; J O Korbel; M U Muckenthaler; A E Kulozik
Journal:  Blood Cancer J       Date:  2017-02-03       Impact factor: 11.037

8.  Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies.

Authors:  Thomas McKerrell; Thaidy Moreno; Hannes Ponstingl; Niccolo Bolli; João M L Dias; German Tischler; Vincenza Colonna; Bridget Manasse; Anthony Bench; David Bloxham; Bram Herman; Danielle Fletcher; Naomi Park; Michael A Quail; Nicla Manes; Clare Hodkinson; Joanna Baxter; Jorge Sierra; Theodora Foukaneli; Alan J Warren; Jianxiang Chi; Paul Costeas; Roland Rad; Brian Huntly; Carolyn Grove; Zemin Ning; Chris Tyler-Smith; Ignacio Varela; Mike Scott; Josep Nomdedeu; Ville Mustonen; George S Vassiliou
Journal:  Blood       Date:  2016-04-27       Impact factor: 25.476

9.  Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms.

Authors:  Chun Hang Au; Anna Wa; Dona N Ho; Tsun Leung Chan; Edmond S K Ma
Journal:  Diagn Pathol       Date:  2016-01-22       Impact factor: 2.644

10.  Evaluation of DNMT3A genetic polymorphisms as outcome predictors in AML patients.

Authors:  Xiao-Qing Yuan; Dao-Yu Zhang; Han Yan; Yong-Long Yang; Ke-Wei Zhu; Yan-Hong Chen; Xi Li; Ji-Ye Yin; Xiao-Lin Li; Hui Zeng; Xiao-Ping Chen
Journal:  Oncotarget       Date:  2016-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.